Context Therapeutics Reports Partial Response in CTIM-76 Phase 1a Trial, Extends Cash Runway
CNTX has more than doubled off its 52-week low of $0.49 on light trading volume (0.3× avg).
Summary
Context Therapeutics reported a confirmed partial response in its Phase 1a trial for CTIM-76 and reiterated its cash runway into mid-2027.
Key Events · Product Development and Regulatory · CNTX
-
Positive Clinical Data for CTIM-76
The company reported a confirmed partial response (cPR) with an 85% reduction in tumor size in a Phase 1a trial patient with platinum-resistant ovarian cancer treated with CTIM-76, its Claudin 6 x CD3 bispecific antibody.
-
Extended Cash Runway
Context Therapeutics reiterated its expected cash runway into mid-2027, providing financial support for its ongoing clinical programs.
-
Upcoming Clinical Milestones
The company anticipates interim Phase 1a data for CTIM-76 in June 2026, interim Phase 1a data for CT-95 in September 2026, and the first patient dosed for CT-202 in Q3 2026.
Analysis · CNTX · Life Sciences
Context Therapeutics has disclosed positive preliminary Phase 1a clinical data for its lead T-cell engager candidate, CTIM-76, showing a confirmed partial response with an 85% tumor reduction in a patient with platinum-resistant ovarian cancer. This is a significant de-risking event for the company's pipeline, demonstrating early efficacy for a key asset. The updated corporate presentation also reiterates a cash runway into mid-2027, providing financial stability for ongoing clinical development. Investors will be watching for further interim data for CTIM-76 in June 2026 and CT-95 in September 2026, as well as the first patient dosing for CT-202 in Q3 2026.
At the time of this filing, CNTX was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.5M. The 52-week trading range was $0.49 to $3.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.